{
    "organizations": [],
    "uuid": "63fe33603d180adacc8e20fd1c2498a2f448b702",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/26/pr-newswire-curis-to-release-first-quarter-2018-financial-results-and-hold-conference-call-on-may-3-2018.html",
    "ord_in_thread": 0,
    "title": "Curis to Release Financial Results and Hold Conference Call on May 3, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "LEXINGTON, Mass., April 26, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT.\nTo access the live conference call, please dial (877) 870-4263 from the United States or (412) 317-0790 from other locations, shortly before 8:30 a.m. EDT. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.\nAbout Curis, Inc.\nCuris is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing ErivedgeÂ® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com .\nView original content: http://www.prnewswire.com/news-releases/curis-to-release-first-quarter-2018-financial-results-and-hold-conference-call-on-may-3-2018-300636882.html\nSOURCE Curis, Inc.",
    "published": "2018-04-26T15:00:00.000+03:00",
    "crawled": "2018-04-26T17:54:20.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "lexington",
        "april",
        "curis",
        "nasdaq",
        "cris",
        "biotechnology",
        "company",
        "focused",
        "development",
        "commercialization",
        "innovative",
        "effective",
        "therapeutic",
        "treatment",
        "cancer",
        "today",
        "announced",
        "company",
        "release",
        "first",
        "quarter",
        "financial",
        "result",
        "thursday",
        "may",
        "financial",
        "market",
        "open",
        "company",
        "management",
        "also",
        "host",
        "conference",
        "call",
        "day",
        "edt",
        "access",
        "live",
        "conference",
        "call",
        "please",
        "dial",
        "united",
        "state",
        "location",
        "shortly",
        "edt",
        "conference",
        "call",
        "also",
        "accessed",
        "curis",
        "website",
        "investor",
        "section",
        "curis",
        "curis",
        "biotechnology",
        "company",
        "focused",
        "development",
        "commercialization",
        "innovative",
        "effective",
        "drug",
        "candidate",
        "treatment",
        "human",
        "cancer",
        "including",
        "investigated",
        "clinical",
        "study",
        "patient",
        "lymphoma",
        "solid",
        "tumor",
        "curis",
        "also",
        "engaged",
        "collaboration",
        "aurigene",
        "area",
        "precision",
        "oncology",
        "part",
        "collaboration",
        "curis",
        "exclusive",
        "license",
        "oral",
        "small",
        "molecule",
        "dual",
        "antagonist",
        "pd1",
        "vista",
        "including",
        "antagonist",
        "oral",
        "small",
        "molecule",
        "dual",
        "antagonist",
        "pd1",
        "tim3",
        "including",
        "antagonist",
        "well",
        "molecule",
        "designed",
        "inhibit",
        "irak4",
        "kinase",
        "including",
        "currently",
        "undergoing",
        "testing",
        "phase",
        "trial",
        "patient",
        "advanced",
        "solid",
        "tumor",
        "lymphoma",
        "phase",
        "trial",
        "india",
        "conducted",
        "aurigene",
        "currently",
        "undergoing",
        "testing",
        "phase",
        "trial",
        "patient",
        "lymphoma",
        "curis",
        "also",
        "party",
        "collaboration",
        "genentech",
        "member",
        "roche",
        "group",
        "genentech",
        "roche",
        "commercializing",
        "treatment",
        "advanced",
        "basal",
        "cell",
        "carcinoma",
        "information",
        "visit",
        "curis",
        "website",
        "view",
        "original",
        "content",
        "http",
        "source",
        "curis",
        "inc"
    ]
}